polycythemia vera

December 30, 2021
prescription for Ropeg

New FDA Approved Treatment for Polycythemia Vera

by David Wallace Patients are Asking – MPN Expert Dr. Abu-Zeinah discusses Ropeginterferon, FDA Approved Treatment for Polycythemia Vera Episode 3 of 3 Ropeginterferon / BESREMi […]
December 27, 2017
Dr Mascarenhas presenting at ASH 2017 on Nutlin

ASH 2017 Nutlin Antagonist Shows Activity in Polycythemia Vera

The investigational Nutlin family antagonist idasanutlin demonstrated significant activity and was well tolerated after multiple cycles of exposure in patients with refractory polycythemia vera (PV). Data […]
June 29, 2017
Pegasys Jakafi combo for MPNs

Minimal Residual Disease or Cure in MPNs? Rationales and perspectives on Combo Therapy with Interferon-alpha2 and Ruxolitinib

This abstract is provided by Mads Emil Bjorn & Hans Carl Hasselbalch – Department of Hematology, Region Zealand, Roskilde, Denmark Abstract Introduction: The therapeutic landscape of […]
April 28, 2017
understanding polycythemia vera

Understanding Polycythemia Vera

Understanding Polycythemia Vera (PV), A Rare Blood Cancer Behind the Mystery, Polycythemia Vera Every year, millions of patients, families and caregivers are impacted by cancer in […]
September 21, 2016
hearing loss in PV

Study Identifies Factors Associated With Hearing Loss in Polycythemia Vera

[contentcards url=”http://www.oncologynurseadvisor.com/leukemia/factors-associated-with-hearing-loss-in-pv-pinpointed/article/523647/” target=”_blank”] “Researchers found that the mean hemoglobin and hematocrit levels of the polycythemia vera group were 16.7 g/dL and 50.4%, respectively, vs 13.4 g/dL […]
September 20, 2016
ropeginterferon

Ropeginterferon alfa-2b, a novel IFNα-2b, induces high response rates with low toxicity in patients with polycythemia vera

Key points The novel IFNα-2b AOP2014 administered once every two weeks (or once a month) has low toxicity and induces high and sustained response rates in […]
MPN Cancer Connection
Malcare WordPress Security